Literature DB >> 33161686

Comparison of Clinical Scoring Systems in the Management of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia

Mehmet Baysal1, Elif Ümit1, Hakkı Onur Kırkızlar1, Ahmet Muzaffer Demir1.   

Abstract

Objective: Several clinical scoring systems have been developed for the differential diagnosis of thrombotic microangiopathies (TMAs), all to predict and identify patients with ADAMTS13 deficiency and to start treatment as soon as possible. The first scoring system in this regard was the Bentley score, and the French score and PLASMIC score were developed afterwards. Materials and
Methods: We aimed to evaluate the laboratory parameters and clinical features of patients who underwent plasma exchange with a prediagnosis of TTP at our clinic between 2007 and 2019 and whose ADAMTS13 enzyme levels were measured and to compare the findings with the scoring systems.
Results: Data of 35 patients were evaluated. Twelve patients were evaluated as high risk according to all three scoring systems. A statistically significant relation was observed between all three scoring systems and ADAMTS13 levels.
Conclusion: A moderate correlation was found between all three scoring systems and ADAMTS13 levels. We observed similar potential strength of all three scoring systems to predict TTP among other TMAs and we conclude that they are applicable in daily practice.

Entities:  

Keywords:  Thrombotic thrombocytopenic purpura; PLASMIC score; Thrombotic microangiopathy; French score; Bentley score

Mesh:

Substances:

Year:  2020        PMID: 33161686      PMCID: PMC7927454          DOI: 10.4274/tjh.galenos.2020.2020.0348

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


  21 in total

1.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Vickie McDonald; Jamie Cavenagh; Beverley J Hunt; Ian Longair; Hannah Cohen; Samuel J Machin
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Thrombotic microangiopathy.

Authors:  M Mörtzell; G Berlin; T Nilsson; C G Axelsson; M Efvergren; J Audzijoni; A Griskevicius; J Ptak; M Blaha; H Tomsova; G M Liumbruno; P Centoni; E Newman; S Eloot; A Dhondt; J Tomaz; V Witt; G Rock; B Stegmayr
Journal:  Transfus Apher Sci       Date:  2011-08-31       Impact factor: 1.764

3.  Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).

Authors:  Neil Shah; Cynthia Rutherford; Karen Matevosyan; Yu-Min Shen; Ravi Sarode
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

4.  Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.

Authors:  J-P Westwood; H Webster; S McGuckin; V McDonald; S J Machin; M Scully
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

5.  Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.

Authors:  Giovanni Luca Tiscia; Angelo Ostuni; Nicola Cascavilla; Filomena Cappucci; Potito Scalzulli; Cosima Battista; Antonio Abrescia; Filippo Aucella; Caterina Buquicchio; Maurizio Brigante; Giovanna D'Andrea; Bruno Di Paolo; Giulio Giordano; Barbara Infante; Silvia Piano; Prudenza Ranieri; Livio Tullo; Elvira Grandone
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

6.  The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.

Authors:  Melissa J Bentley; Chris M Lehman; Robert C Blaylock; Andrew R Wilson; George M Rodgers
Journal:  Transfusion       Date:  2010-04-20       Impact factor: 3.157

7.  ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.

Authors:  Chong H Kim; Sierra C Simmons; Lance A Williams; Elizabeth M Staley; X Long Zheng; Huy P Pham
Journal:  Transfusion       Date:  2017-06-23       Impact factor: 3.157

8.  External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.

Authors:  A Li; P R Khalighi; Q Wu; D A Garcia
Journal:  J Thromb Haemost       Date:  2017-11-16       Impact factor: 5.824

9.  Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.

Authors:  Ning Tang; Xiong Wang; Dengju Li; Ziyong Sun
Journal:  Thromb Res       Date:  2018-10-12       Impact factor: 3.944

10.  Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.

Authors:  M J Bentley; A R Wilson; G M Rodgers
Journal:  Vox Sang       Date:  2013-05-11       Impact factor: 2.144

View more
  2 in total

1.  Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan.

Authors:  Chun-Hui Lee; Yi-Ching Huang; Sin-Syue Li; Ya-Ting Hsu; Ya-Ping Chen; Tsai-Yun Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-09

Review 2.  Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children.

Authors:  Cecile L Karsenty; Susan E Kirk; Hannah L Helber; Jose M Esquilin; Jenny M Despotovic; Amanda B Grimes
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.